Powell David J, Hertzberg Robert P, Macarrόn Ricardo
Alternative Drug Discovery, GSK Pharmaceuticals, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK.
GSK Pharmaceuticals R&D, Philadelphia, PA, USA.
Methods Mol Biol. 2016;1439:1-32. doi: 10.1007/978-1-4939-3673-1_1.
HTS remains at the core of the drug discovery process, and so it is critical to design and implement HTS assays in a comprehensive fashion involving scientists from the disciplines of biology, chemistry, engineering, and informatics. This requires careful consideration of many options and variables, starting with the choice of screening strategy and ending with the discovery of lead compounds. At every step in this process, there are decisions to be made that can greatly impact the outcome of the HTS effort, to the point of making it a success or a failure. Although specific guidelines should be established to ensure that the screening assay reaches an acceptable level of quality, many choices require pragmatism and the ability to compromise opposing forces.
高通量筛选（HTS）仍然是药物发现过程的核心，因此以全面的方式设计和实施高通量筛选分析至关重要，这涉及生物学、化学、工程学和信息学等学科的科学家。这需要仔细考虑许多选择和变量，从筛选策略的选择开始，到先导化合物的发现结束。在这个过程的每一步，都要做出可能极大影响高通量筛选工作结果的决策，甚至决定其成败。虽然应该制定具体的指导方针以确保筛选分析达到可接受的质量水平，但许多选择需要务实态度以及平衡相互冲突因素的能力。
